ReviewNature reviews. Rheumatology2020
Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Pooled it
- Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis.PloS one · 2023Pooled it
- Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.Frontiers in immunology · 2022Pooled it
- Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Saccharomyces boulardii improves clinical and paraclinical indices in overweight/obese knee osteoarthritis patients: a randomized triple-blind placebo-controlled trial.European journal of nutrition · 2024Trial
- Cartilage-targeting engineered probiotic bacterial extracellular vesicles treat osteoarthritis through modulation of matrix homeostasis.Materials today. Bio · 2026Article
- [Psoriatic arthritis as MHC-I-associated disease].Zeitschrift fur Rheumatologie · 2026Review
- The Integrin Signature of Ankylosing Spondylitis: Divergent Regulation of CD29 and CD49b in HLA-B27-Positive Cohorts in Iraqi Patients.Iranian journal of pathology · 2026Article
- Gut microbe-derived short-chain fatty acids regulate alphavirus arthritis and macrophage activation in mice.The Journal of clinical investigation · 2026Article
- Review
- Dietary protein, major dietary protein sources, and chronic joint diseases risk.Nutrition & metabolism · 2026Article
- Inflammatory Bowel Disease-Associated Spondyloarthritis.Journal of clinical medicine · 2026Review
- Intestinal microbiota and arthritis.EULAR rheumatology open · 2026Review
- The gut-joint axis in juvenile idiopathic arthritis.Arthritis research & therapy · 2026Review
- Gut microbiota and bone aging: Focusing on the gut-X axis modes.Journal of orthopaedic translation · 2026Review
- Gut dysbiosis and inflammation in patients with Juvenile Idiopathic Arthritis-Enthesitis Related Arthritis: impact of HLA-B27 status.Clinical rheumatology · 2026Article
- Single-cell atlas of axial skeletal immune-matrix interaction in spondylitis.Immunologic research · 2026Article
- Serum immune profiling suggests overlap between IBD patients with joint complaints and patients with spondyloarthritis.Frontiers in immunology · 2026Article
- The brain-gut-joint axis in arthritis: crosstalk, treatment, and future perspectives.Journal of orthopaedic translation · 2026Review
- Gut microbiota dysbiosis and joint diseases: advances in the gut-joint axis.Frontiers in immunology · 2026Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut inflammation is strongly associated with spondyloarthritis (SpA), as exemplified by the high prevalence of inflammatory bowel disease (IBD) and the even higher occurrence of subclinical gut inflammation in patients with SpA. The gut-joint axis of inflammation in SpA is further reinforced by similarities in immunopathogenesis at both anatomical sites and by the clinical success of therapies blocking TNF and IL-23 in IBD and in some forms of SpA. Many genetic risk factors are shared between SpA and IBD, and changes in the composition of gut microbiota are seen in both diseases. Current dogma is that inflammation in SpA initiates in the gut and leads to joint inflammation; however, although conceptually attractive, some research does not support this causal relationship. For example, therapies targeting IL-17A are efficacious in the joint but not the gut, and interfering with gut trafficking by targeting molecules such as α4β7 in IBD can lead to onset or flares of SpA. Several important knowledge gaps remain that must be addressed in future studies. Determining the true nature of the gut-joint axis has real-world implications for the treatment of patients with co-incident IBD and SpA and for the repurposing of therapeutics from one disease to the other.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.